At page 4, between lines 16 and 17 of text, please insert:

--BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graphical representation of the mean blood levels of cyclosporin PSC 833 in dogs as a function of time, as determined by radioimmunoassay.--

At page 4, after the BRIEF DESCRIPTION OF THE DRAWINGS added via the above amendment, please insert:

--DETAILED DESCRIPTION OF THE INVENTION--.

At page 28, please replace the Abstract with the following:

--ABSTRACT

The present invention is directed to solution concentrates for intravenous administration of an emulsion prepared from the concentrate, the concentrate containing [3'-desoxy-3-oxo-MeBmt]¹- [Val]²-Ciclosporin as active agent, oleic acid or a salt thereof, or palmitoyl oleoyl phosphatidylglycerol (POPG) or a salt thereof as a stabiliser, and ethanol, wherein the concentrate is free of poly(oxyethylene)-40-castor oil and wherein the weight ratio of active agent to stabiliser is from 400:1 to 10:1, as well as emulsions prepared from the concentrates and a placebo fat emulsion.--

In the Claims:

In claim 1, line 1 delete "for intravenous administration of an emulsion".

In claim 1, line 2, before "oleic" insert --a stabiliser selected from--.

Please add the following new claims:

--6. An emulsion for oral administration comprising the concentrate of claim 1 and a placebo fat emulsion.

A method of treatment and prevention of transplant rejection, autoimmune disease and of inflammatory conditions which method comprises administering an effective amount a concentrate of claim 1 to a subject in need of such treatment.

A concentrate consisting essentially of

a) a [3'-desoxy-3-oxo-MeBmt]¹-[Val]²-Ciclosporin as active agent,

- 2 -

3\